Please login to the form below

Not currently logged in
Email:
Password:

Sanofi CEO Viehbacher to head EFPIA

Assumes presidency at European trade body

Sanofi EFPIA Christopher ViehbacherChristopher Viehbacher, CEO of Sanofi, has assumed his position as president of the trade body the European Federation of Pharmaceutical Indsutries and Asoications (EFPIA).

He was elected to the position in November 2012 to replace GlaxoSmithKline's Andrew Witty, and will remain as president for two years during which time he will lead the pharma indsutry's main voice in Europe in working with the EU and member states.

Viehbacher said he was “extremely honoured” with his election, and commented that economic challenges mean a different approach to healthcare is needed going forward.

“[G]iven the chronic deficits of healthcare systems, we must work differently, build collaborative policies and combine our strengths at both national and European levels,” he said.

“As we want healthcare to be a growth engine for Europe, our industry must focus on three priorities: patient access, science & innovation and competitiveness.”

One of the most pressing matters for EFPIA is the seemingly inevitable trend towards transparency of trial data, and Viehbacher has already commented on the subject.

He said that the stance taken by the European Medicines Agency (EMA) threatens to make commercially confidential information available to competitors around the world and any change has to be carried out "intelligently" to avoid damaging the sector.

In addition to serving as CEO of Sanofi since 2008, Viehbacher is also chairman of Genzyme, which Sanofi acquired in 2011, and has held the chair at US pharma body PhRMA between December 2010 and April 2012.

He started his career in finance at PriceWaterhouseCoopers before joining GlaxoSmithKline in 1988, rising to president of Pharmaceutical Operations North America before joining Sanofi.

26th June 2013

From: Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics